
AstraZeneca is one step closer to acquiring Alexion Pharmaceuticals having been cleared by the US Federal Trade Commission after an antitrust review, the company stated.
The Cambridge, UK, pharmaceutical and biotechnology company said the US clearance follows competition clearances in Canada, Brazil, Russia, and other countries globally.
“Additional global regulatory clearances are pending, including but not limited to the UK, EU and Japan,” the company added.
The deal is valued at US$39 billion. AstraZeneca expects to close the acquisition in the third quarter.
AstraZeneca in December agreed to pay US$175 a share for the Boston pharmaceutical company, which is known for its focus on rare and ultra-rare disease. Alexion holders will own around 15% of AstraZeneca’s shares outstanding when the deal closes.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta’s $220 Million Fine in Nigeria Upheld by Competition Tribunal
Apr 27, 2025 by
CPI
DoorDash Proposes $3.6 Billion Acquisition of Deliveroo
Apr 27, 2025 by
CPI
US Judge Delays Approval of $2.8 Billion NCAA Settlement Over Athlete Rights
Apr 27, 2025 by
CPI
US Launches Criminal Antitrust Probe Into TP-Link’s Pricing Practices
Apr 27, 2025 by
CPI
CK Hutchison’s $22.8 Billion Port Sale to BlackRock Draws Chinese Scrutiny
Apr 27, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece